Institut Jantung Negara - National Heart Institute

Kuala Lumpur 50400

1 studies enrolling now · 14 studies all time

What they study most

CIED Related Infection, Chronic Thromboembolic Pulmonary Hypertension, Class I or II Indication for Implantation of a Single Chamber Ventricular Pacemaker According to ACC/AHA/HRS 2001 Guidelines and Any National Guidelines, Heart Failure, Heart Failure With Preserved Ejection Fraction (HFpEF), Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Tachyarrhythmias, Ventricular Dysfunction

Studies at this site

• ELEVATE-HFpEF Clinical Study — Recruiting now
• A Clinical Study of to Confirm the Doses of Selexipag in Children With Pulmonary Arterial Hypertension — Running, not enrolling
• Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension — Running, not enrolling
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) — Completed
• Selexipag (ACT-293987) in Pulmonary Arterial Hypertension — Completed
• REPAIR: Right vEntricular Remodeling in Pulmonary ArterIal hypeRtension — Completed
• Clinical Study to Assess the Long-term Safety and Tolerability of ACT 064992 in Patients With Symptomatic Pulmonary Arterial Hypertension — Completed
• A Study to Find Out if Selexipag is Effective and Safe in Patients With Chronic Thromboembolic Pulmonary Hypertension When the Disease is Inoperable or Persistent/Recurrent After Surgery and/or Interventional Treatment — Stopped early
• Personalized CRT - MPP Post Approval Study — Completed
• Attain Stability™ Quad Clinical Study — Completed
• World-wide Randomized Antibiotic Envelope Infection Prevention Trial — Completed
• Micra Transcatheter Pacing Study — Completed
• Safety and Clinical Performance of the Protecta ICD and CRT-D — Completed
• Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension — Completed